Abstract
Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of molecules including β-adrenergic blockers, cholinergic agents, α -adrenergic agonists, carbonic anhydrase inhibitors and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.
Original language | English (US) |
---|---|
Pages (from-to) | 181-194 |
Number of pages | 14 |
Journal | Expert Opinion on Drug Safety |
Volume | 1 |
Issue number | 2 |
DOIs | |
State | Published - Jul 1 2002 |
Keywords
- carbonic anhydrase inhibitors
- cholinergic agents
- glaucoma
- long-term safety
- ocular hypotensive lipids
- α-adrenergic agonists
- β-adrenergic blockers
ASJC Scopus subject areas
- Pharmacology (medical)